X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/leap-therapeutics-announces-40-million-private-placement-302114324.html
https://www.prnewswire.com/news-releases/leap-therapeutics-announces-initiation-of-randomized-controlled-part-b-of-the-defiance-study-of-dkn-01-in-colorectal-cancer-patients-301875024.html
https://www.prnewswire.com/news-releases/leap-therapeutics-announces-completion-of-enrollment-in-part-a-of-the-defiance-study-of-dkn-01-for-the-treatment-of-colorectal-cancer-patients-301794583.html
https://www.fiercebiotech.com/biotech/beigene-pulls-out-leap-faith-letting-option-immuno-oncology-candidate-lapse
https://www.biopharmadive.com/news/leap-therapeutics-acquire-flame-biosciences-stock-merger-cancer/640478/
https://www.prnewswire.com/news-releases/leap-therapeutics-announces-first-patient-enrolled-in-defiance-study-of-dkn-01-for-the-treatment-of-colorectal-cancer-patients-301649992.html
https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-initial-data-from-the-investigator-sponsored-study-of-dkn-01-plus-docetaxel-in-patients-with-prostate-cancer-at-the-2022-asco-annual-meeting-301555696.html
https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-raymond-james-43rd-annual-institutional-investors-conference-301493060.html
https://www.prnewswire.com/news-releases/leap-therapeutics-announces-closing-of-public-offering-of-common-stock-and-pre-funded-warrants-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301384798.html
https://seekingalpha.com/news/3741996-leap-therapeutics-plunges-on-stock-and-pre-funded-warrants-offering
Market Place
Share 
